We constructed a prognostic model for HBV-HCC that includes five genes: DLAT, STC2, POF1B, S100A9, and CPS1. We analyzed the tumor microenvironment of different risk groups and assessed the efficacy of immunotherapy and drug treatment based on risk scores. Here, DLAT is linked to hepatocellular carcinoma.